Axsome Therapeutics has reached a settlement agreement with Hetero Labs Ltd. to resolve patent litigation concerning Axsome's product SUNOSI® (solriamfetol). The legal dispute arose after Hetero submitted an Abbreviated New Drug Application to the U.S. FDA to market a generic version of SUNOSI. According to the settlement terms, Hetero is permitted to sell its generic version starting on or after September 1, 2040, if pediatric exclusivity is granted, or on or after March 1, 2040, if not, contingent upon FDA approval. The agreement will be reviewed by the U.S. Federal Trade Commission and the U.S. Department of Justice. Other similar patent litigations remain ongoing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.